WELLCOVORIN
LOE ApproachingNDAORALTABLET
Approved
Jul 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WELLCOVORIN is an oral small-molecule tablet approved by GSK in 1983. The specific indication and mechanism of action are not disclosed in available data, limiting clinical characterization. This is a legacy product in the small-molecule space with established market presence.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% index); team likely focused on lifecycle extension or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
WELLCOVORIN offers limited near-term career growth; no linked job openings currently available. Working on a LOE-approaching asset requires strategic focus on cost optimization, market access, and competitive defense rather than revenue expansion.
Brand ManagerProduct Manager
Worked on WELLCOVORIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.